CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
VBL Therapeutics is developing VB-111, a novel gene therapy targeting the tumor environment to treat various solid tumors, starting with ovarian cancer. This approach aims to disrupt blood supply to tumors while activating the immune response, potentially overcoming treatment resistance.
VBL therapeutics is a late-stage clinical biopharmaceutical company focused on first in class treatments for cancer. VBL's lead oncology product candidate, VB-111, is an innovative targeted anti-cancer gene therapy with potential to treat a wide range of solid tumors.
Most cancer therapies aim to target tumors cells while sparing normal cells, but tumors are heterogeneous and often develop resistance to treatment.
Instead of targeting the tumor directly, VB-111 targets the tumor environment by d…
VASCULAR BIOGENICS LTD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
